CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-12 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $7.39 | $185K | 943,514 |
| 2023-12-12 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,147,635 | ||
| 2023-12-12 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.40 | $85K | 7,384,526 |
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 829,907 | ||
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 819,907 | ||
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 851,157 |
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Sale | −59,829 | $7.49 | $448K | 791,328 |
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 406,250 | ||
| 2023-12-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,491,496 | ||
| 2023-11-28 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.72 | $77K | 7,395,973 |
| 2023-11-16 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +3,000 | $1.06 | $3K | 416,404 |
| 2023-11-16 | Larson Tina Marriott President and COO | Sale 10b5-1 | −3,000 | $6.76 | $20K | 413,404 |
| 2023-11-16 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 520,000 | ||
| 2023-11-15 | Larson Tina Marriott President and COO | Shares withheld for taxes 10b5-1 | −5,378 | $7.18 | $39K | 413,404 |
| 2023-11-15 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +18,000 | $2.22 | $40K | 158,351 |
| 2023-11-15 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −18,000 | $6.51 | $117K | 140,351 |
| 2023-11-15 | Virani Shafique Chief Business Officer | Shares withheld for taxes 10b5-1 | −3,603 | $7.18 | $26K | 136,748 |
| 2023-11-15 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −18,000 | 397,469 | ||
| 2023-11-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −16,913 | $7.18 | $121K | 819,907 |
| 2023-11-15 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 963,186 |
Page 28 of 41 · 805 trades